Group 1 - The company Kunlun Energy (00135) announced the appointment of Mr. Xin Dinghua as the Chief Independent Non-Executive Director, effective from March 24, 2026 [2]

Group 1 - The core viewpoint of the article is that Daphne International (00210) reported a 13% increase in revenue for the fiscal year ending December 31, 2025, amounting to approximately 364 million HKD, with a 9% rise in profit attributable to shareholders reaching about 117 million HKD [3] - The basic earnings per share are reported at 0.059 HKD, and the company has proposed a final dividend of 0.02 HKD per share [3] - The revenue growth is primarily driven by an 18% increase in licensing fee income from mainland China, rising from approximately 127 million RMB to about 150 million RMB, attributed to an increase in the number of licensed footwear and accessory products sold to online franchisees [3] Group 2 - Wholesale product sales revenue for the fiscal year is approximately 189 million RMB, up 9% from 175 million RMB in 2024, mainly due to increased sales volume to franchisees [3]

Group 1 - The company, Daphne International (00210), announced that it will distribute a final dividend of HKD 0.02 per share on June 25, 2026 [2]

Group 1 - The core point of the article is that Li Auto announced a share repurchase plan allowing the company to buy back up to $1 billion of its Class A common stock and/or American Depositary Shares by March 31, 2027, which led to a pre-market stock price increase of over 4% [2][3] - On March 12, Li Auto reported its 2025 financial results, revealing a net profit of just over 1.1 billion yuan, a significant decline of nearly 86% year-on-year, with revenue shrinking by 22% to 112.3 billion yuan [3] - The company's operating profit and net profit both saw a substantial drop in the fourth quarter, contrasting with many other automakers that experienced a surge in sales during the same period [3]

Group 1 - Li Auto (LI.US) opened with a gain of over 5%, reaching $17.98 [3] - On March 24, Li Auto announced that its board approved a share repurchase plan, authorizing the purchase of up to $1 billion of Class A common stock and/or American Depositary Shares from the approval date until March 31, 2027 [3] - International oil prices rose again, with Brent crude futures increasing by over 4% to $99.85 [3] Group 2 - Goldman Sachs analysts noted that rising oil prices will accelerate the global adoption of electric vehicles, while the ongoing decline in lithium prices is improving battery economics and pricing competitiveness [3]

Group 1 - The company, Li Auto, has announced a share repurchase plan authorized by its board of directors, allowing the repurchase of up to $1 billion of its Class A ordinary shares and/or American depositary shares from March 24, 2026, to March 31, 2027 [3] - The board believes that the share repurchase plan reflects strong confidence in the company's strategic roadmap and future value creation, which is expected to benefit the company and create value for shareholders [3]

Core Viewpoint - The strategic cooperation agreement between the company and Eli Lilly for drug development in oncology and immunology has been approved and is now effective as of March 24, 2026 [1] Group 1: Strategic Cooperation Agreement - The company announced the signing of a strategic cooperation agreement with Eli Lilly to advance new drug development in oncology and immunology [1] - The agreement has received early approval from the Federal Trade Commission, fulfilling all conditions for its effectiveness [1] - The strategic cooperation agreement officially became effective on March 24, 2026 [1] Group 2: Clarification on Misinterpretations - The company clarified that some media reports incorrectly interpreted the effectiveness of the strategic cooperation agreement as an acquisition of the company [1] - The company emphasized that it has no intention of engaging in any acquisition transactions [1] - Shareholders and potential investors are advised not to rely on market rumors and should refer only to the company's official announcements for information [1]

Core Viewpoint - The company reported a revenue of 575.2 billion yuan in 2025, a decrease of 1.6% year-on-year, and a net profit attributable to shareholders of 7.16 billion yuan, an increase of 1.5% year-on-year, aligning with Wind consensus expectations [1] Group 1: Revenue and Profit Performance - The company's revenue and profit growth showed marginal improvement compared to the first three quarters of 2025, primarily due to the resilience in the pharmaceutical and medical device distribution sectors [1] - The retail sector's revenue growth was driven by enhanced "integrated wholesale and retail" and "dual-brand" collaborative income growth [1] - The profit growth outpaced revenue growth due to cost reduction and efficiency improvements, with an overall expense ratio decreasing by 0.25 percentage points [1] Group 2: Pharmaceutical Distribution - The pharmaceutical distribution segment generated revenue of 435.4 billion yuan in 2025, down 2.02% year-on-year, with an operating profit margin of 2.73%, remaining stable compared to the previous year [2] - The segment is expected to stabilize in 2026 due to ongoing optimization of product categories and strengthening market share in collective procurement and national negotiations [2] - The company is enhancing direct sales to high-tier hospitals and retail terminals while adjusting the product mix towards high-demand and high-value clinical needs [2] Group 3: Medical Device Distribution - The medical device distribution segment reported revenue of 115.5 billion yuan in 2025, also down 2.02% year-on-year, primarily due to deepening collective procurement in medical devices [2] - The outlook for 2026 is positive, driven by improved account management and a focus on high-value business segments [2] - The company is expanding its SPD (Supply, Processing, and Distribution) business, with a significant increase in project numbers and revenue growth [2] Group 4: Retail Business - The retail business achieved revenue of 38.4 billion yuan in 2025, an increase of 6.67% year-on-year, led by the professional pharmacy segment [3] - The operating profit margin for the retail segment improved to 1.56%, up 0.66 percentage points year-on-year, due to cost control measures [3] - The company anticipates continued revenue growth in 2026, supported by the strengthening of the professional pharmacy system and strategic store closures to enhance profitability [3] Group 5: Earnings Forecast and Valuation - The company projects EPS of 2.50, 2.71, and 2.89 yuan for 2026, 2027, and 2028 respectively, with a target price of 22.53 HKD based on an 8.2x PE ratio for 2026 [3]

Core Viewpoint - The company benefits from rapid growth in its Hong Kong and Thailand businesses, with a 15% year-on-year increase in NBV, while the NBV growth momentum in mainland China accelerates in the second half of the year, reaching a 14% year-on-year increase [1][5] Group 1: NBV Growth - The company's NBV for 2025 is projected to increase by 15% to $5.516 billion, with annualized new premiums up by 9% and NBVM increasing by 3.6 percentage points to 58.5% [1] - The growth in NBV is primarily driven by the Hong Kong and Thailand markets, with Hong Kong's NBV increasing by 28% to $2.256 billion and Thailand's NBV increasing by 13% to $993 million [1][2] - In mainland China, the NBV growth is 2% year-on-year, with a significant acceleration in the second half of the year, reaching a 14% increase, and a projected growth rate exceeding 20% in January-February 2026 [1][5] Group 2: Operating Profit and Financial Performance - The company's operating profit for the year is $7.136 billion, reflecting a 7% year-on-year increase, with earnings per share rising by 12% [2] - The strong performance in insurance services, which increased by 18% to $6.772 billion, is a key driver of this growth, supported by a 10% increase in CSM release [2] - The company's embedded value operating profit is $10.887 billion, with a year-on-year increase of 13% and an embedded value return of 15.8% [2][3] Group 3: Shareholder Returns - The company has declared a final dividend of 144.08 Hong Kong cents per share, resulting in a total annual dividend of 193.08 Hong Kong cents per share, an increase of 10% [3][4] - The board has approved a new share buyback program of $1.7 billion, reflecting a commitment to returning capital to shareholders [3][4] - The company aims to distribute 75% of its generated free surplus, with a reported free surplus net of $4.451 billion for the year, up 11% year-on-year [4]

Core Viewpoint - Geely Auto reported a revenue of 345.2 billion yuan for 2025, a year-on-year increase of 25%, with a net profit attributable to shareholders of 16.85 billion yuan, up 0.2% year-on-year. The core net profit, excluding foreign exchange gains and losses, reached 14.41 billion yuan, a year-on-year increase of 36% [1] Group 1: Financial Performance - In Q4 2025, Geely's revenue was 105.8 billion yuan, a year-on-year increase of 22% and a quarter-on-quarter increase of 19%, with a sales volume of 854,000 vehicles, up 24% year-on-year and 12% quarter-on-quarter [1] - The gross profit margin for Q4 2025 was 16.9%, a decrease of 0.5 percentage points year-on-year but an increase of 0.3 percentage points quarter-on-quarter [1] - Investment income for Q4 2025 was 930 million yuan, an increase of 430 million yuan year-on-year and 570 million yuan quarter-on-quarter [1] Group 2: Product Strategy and Sales Goals - Geely plans to launch over 10 new models in 2026, continuing a strong new product cycle, with a sales target of 3.45 million vehicles, representing a 14% year-on-year increase [2] - The high-end product strategy is progressing well, with the launch of flagship models such as the Galaxy M9, Lynk & Co 900, and Zeekr 9X in 2025 [2] - The Zeekr 8X, a flagship SUV, was launched with a pre-sale price range of 376,800 to 516,800 yuan, achieving over 10,000 orders in just 38 minutes [2] Group 3: Profit Growth and Market Outlook - Geely's high-end and export strategies are expected to drive profit growth, with a target of 640,000 vehicles for export in 2026, a year-on-year increase of 52% [3] - The automotive industry is showing signs of recovery, with improved expectations for electric vehicle exports following recent oil and gas price increases [3] - The company is projected to achieve a price-to-earnings ratio (PE) of 8 times in 2026, with potential for valuation recovery as industry expectations improve [3] Group 4: Strategic Integration and Technological Advancements - Geely is advancing strategic integration under the "Taizhou Declaration," aiming to optimize sales, management, and R&D expense ratios through technology sharing and joint procurement [4] - The year 2025 marks a critical turning point for Geely's "Smart Geely 2025" strategy, transitioning from investment to realization of smart technology [4] - Collaborations with partners like Samsung and Changxin are expected to yield new technologies and cost advantages in core components, enhancing competitive strength in the second half of the smart competition [4] Group 5: Earnings Forecast and Valuation - The forecast for Geely's net profit for 2026-2027 has been adjusted to 25 billion and 27.8 billion yuan, respectively, with a projected PE of 8.0 times, 6.9 times, and 6.3 times for 2028 [5] - Based on historical valuation levels and recent industry performance, the target PE for 2026 has been raised to 10-12 times, corresponding to a target price of 26.17-31.40 HKD, indicating a potential upside of 25-50% [5]